<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28323">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01786616</url>
  </required_header>
  <id_info>
    <org_study_id>UCSC-AG-16</org_study_id>
    <nct_id>NCT01786616</nct_id>
  </id_info>
  <brief_title>Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma</brief_title>
  <official_title>Polymorphism of beta2-adrenoceptor and Regular Use of Formoterol in Asthma: Preliminary Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University, Italy</source>
  <oversight_info>
    <authority>Italy: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polymorphism at codon 16 of the beta2-adrenoceptor (beta2-AR) affects the responsiveness to
      salmeterol in asthmatics. Data concerning formoterol are more controversial in literature.
      The aim of this study was to verify whether  homozygote for arginine-16 (ArgArg16) and
      homozygote for glycine-16 (GlyGly16) genotypes differently influence the long-term
      responsiveness to formoterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Peak Expiratory Flow (PEF) variability</measure>
    <time_frame>PEF has been monitorized during the 4-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 sec (FEV1) slope of the dose-response curve to salbutamol</measure>
    <time_frame>At the end of the 4-week treatment period</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Formoterol</arm_group_label>
    <description>12 mcg BID for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol</intervention_name>
    <arm_group_label>Formoterol</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      white cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pneumological outpatient clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mild to moderate asthma

          -  Stable clinical conditions

        Exclusion Criteria:

          -  Smokers

          -  Current therapy with oral steroids

          -  Exacerbations within the past 3 months
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic University, Pneumology Unit</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 6, 2013</lastchanged_date>
  <firstreceived_date>January 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University, Italy</investigator_affiliation>
    <investigator_full_name>Leonello Fuso</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Formoterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
